XML 21 R11.htm IDEA: XBRL DOCUMENT v3.23.2
Product Revenue, Net
 6 Months Ended
Jun. 30, 2023
Revenue from Contract with Customer [Abstract]  
Product Revenue, Net PRODUCT REVENUE, NET
We received approval from the FDA in September 2019 to market IBSRELA in the U.S. We began selling IBSRELA in the U.S. in March 2022. We distribute IBSRELA principally through major wholesalers, specialty pharmacies and group purchasing organizations ("GPOs") (collectively, our "Customers"). Our Customers subsequently sell IBSRELA to pharmacies and patients. Separately, we enter into arrangements with third parties that provide for government-mandated rebates, chargebacks and discounts. Revenue from product sales is recognized when our performance obligations are satisfied, which is when Customers obtain control of our product and occurs upon delivery.

During the three and six months ended June 30, 2023, we recorded net revenue for IBSRELA of $18.3 million and $29.7 million, respectively. During the three and six months ended June 30, 2022, we recorded net revenue for IBSRELA of $1.6 million and $2.0 million, respectively.

Revenue from the following Customers who contributed greater than 10% of our product revenue, net during the three and six months ended June 30, 2023 and 2022 as a percentage of total product revenue, net was as follows:
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Cardinal Health22.4 %22.7 %22.3 %21.7 %
AmerisourceBergen Drug Corporation21.1 %40.2 %21.3 %35.1 %
McKesson Corporation18.4 %24.6 %19.4 %22.5 %
BioRidge Pharma, LLC20.0 %— %19.0 %— %
The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):
Discounts and ChargebacksRebates, Wholesaler and GPO FeesCopay and ReturnsTotal
Balance as of December 31, 2022$142 $1,444 $1,258 $2,844 
Provisions1,978 5,724 5,272 12,974 
Credits/payments(1,782)(4,325)(3,864)(9,971)
Balance as of June 30, 2023$338 $2,843 $2,666 $5,847